169 related articles for article (PubMed ID: 33610543)
1. Prognosis of Interval Distant Metastases After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.
Kroese TE; Dijksterhuis WPM; van Rossum PSN; Verhoeven RHA; Mook S; Haj Mohammad N; Hulshof MCCM; van Berge Henegouwen MI; van Oijen MGH; Ruurda JP; van Laarhoven HWM; van Hillegersberg R
Ann Thorac Surg; 2022 Feb; 113(2):482-490. PubMed ID: 33610543
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population-based study.
Pape M; Vissers PAJ; de Vos-Geelen J; Hulshof MCCM; Gisbertz SS; Jeene PM; van Laarhoven HWM; Verhoeven RHA
Cancer Sci; 2022 Mar; 113(3):1038-1046. PubMed ID: 34986523
[TBL] [Abstract][Full Text] [Related]
3. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.
Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M
Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555
[TBL] [Abstract][Full Text] [Related]
4. Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis.
Liu T; Ding S; Dang J; Wang H; Chen J; Li G
Radiat Oncol; 2019 Oct; 14(1):176. PubMed ID: 31619265
[TBL] [Abstract][Full Text] [Related]
5. [The value of the planned neoadjuvant radiotherapy or chemoradiotherapy for the non-radical resection of esophageal squamous cell carcinoma].
Ni WJ; Deng W; Xiao ZF; Zhou ZM; Wang X; Chen DF; Feng QF; Liang J; Lyu JM; Bi N; Deng L; Zhang T; Wang WQ; Xue Q; Gao SG; Mu JW; Mao YS; Wang DL; Zhao J; Gao YS; Huang JF; Tan FW; Zhao L; Lyu F; Zhang GC
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):295-302. PubMed ID: 31014056
[No Abstract] [Full Text] [Related]
6. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
7. Postoperative adjuvant chemotherapy versus chemoradiotherapy for node-positive esophageal squamous cell carcinoma: a propensity score-matched analysis.
Wang Q; Lang J; Li T; Peng L; Dai W; Jiang Y; Xie T; Fang Q; Wang Y; Wu L; Cao B; Han Y
Radiat Oncol; 2020 May; 15(1):119. PubMed ID: 32448253
[TBL] [Abstract][Full Text] [Related]
8. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.
Barbetta A; Hsu M; Tan KS; Stefanova D; Herman K; Adusumilli PS; Bains MS; Bott MJ; Isbell JM; Janjigian YY; Ku GY; Park BJ; Wu AJ; Jones DR; Molena D
J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2710-2721.e3. PubMed ID: 29548582
[TBL] [Abstract][Full Text] [Related]
9. Trends in treatment and overall survival among patients with proximal esophageal cancer.
de Vos-Geelen J; Geurts SM; van Putten M; Valkenburg-van Iersel LB; Grabsch HI; Haj Mohammad N; Hoebers FJ; Hoge CV; Jeene PM; de Jong EJ; van Laarhoven HW; Rozema T; Slingerland M; Tjan-Heijnen VC; Nieuwenhuijzen GA; Lemmens VE
World J Gastroenterol; 2019 Dec; 25(47):6835-6846. PubMed ID: 31885424
[TBL] [Abstract][Full Text] [Related]
10. A Propensity-matched Analysis Comparing Survival After Esophagectomy Followed by Adjuvant Chemoradiation to Surgery Alone for Esophageal Squamous Cell Carcinoma.
Hwang JY; Chen HS; Hsu PK; Chao YK; Wang BY; Huang CS; Liu CC; Wu SC
Ann Surg; 2016 Jul; 264(1):100-6. PubMed ID: 26649580
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer.
Chen PJ; Yap WK; Chang YC; Tseng CK; Chao YK; Hsieh JC; Pai PC; Lee CH; Yang CK; Ho AT; Hung TM
BMC Cancer; 2020 Jun; 20(1):545. PubMed ID: 32522275
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of lymphovascular invasion in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
Chen WH; Huang YL; Chao YK; Yeh CJ; Chang HK; Tseng CK; Liu YH
Ann Surg Oncol; 2015 Jan; 22(1):338-43. PubMed ID: 25023545
[TBL] [Abstract][Full Text] [Related]
13. Treatment strategies in recurrent esophageal or junctional cancer.
Butter R; Lagarde SM; van Oijen MGH; Anderegg MCJ; Gisbertz SS; Meijer SL; Hulshof MCCM; Bergman JJGHM; van Berge Henegouwen MI; van Laarhoven HWM
Dis Esophagus; 2017 Sep; 30(9):1-9. PubMed ID: 28859371
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trial.
Yu E; Allan AL; Sanatani M; Lewis D; Warner A; Dar AR; Yaremko BP; Lowes LE; Palma DA; Raphael J; Vincent MD; Rodrigues GB; Fortin D; Inculet RI; Frechette E; Bierer J; Law J; Younus J; Malthaner RA
BMC Cancer; 2022 Jul; 22(1):746. PubMed ID: 35804307
[TBL] [Abstract][Full Text] [Related]
15. Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.
Tanaka T; Ueno M; Iizuka T; Hoteya S; Haruta S; Udagawa H
Dis Esophagus; 2019 Dec; 32(12):. PubMed ID: 30980070
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
Yap WK; Chang YC; Tseng CK; Hsieh CH; Chao YK; Su PJ; Hou MM; Yang CK; Pai PC; Lin CR; Hsieh CE; Wu YY; Hung TM
Dis Esophagus; 2017 Aug; 30(8):1-10. PubMed ID: 28575243
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.
Yen YC; Chang JH; Lin WC; Chiou JF; Chang YC; Chang CL; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
Cancer; 2017 Jun; 123(11):2043-2053. PubMed ID: 28152166
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
Leng X; He W; Yang H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Liu H; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Fu J; Han Y
Ann Surg; 2021 Dec; 274(6):e1022-e1029. PubMed ID: 31855875
[TBL] [Abstract][Full Text] [Related]
19. Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?
Anand S; Bhati G; Gurram R; Gnanasekaran S; Kate V; Pottakkat B; Kalayarasan R
J Gastrointest Cancer; 2021 Jun; 52(2):659-665. PubMed ID: 32607960
[TBL] [Abstract][Full Text] [Related]
20. Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched Study.
van der Wilk BJ; Noordman BJ; Neijenhuis LKA; Nieboer D; Nieuwenhuijzen GAP; Sosef MN; van Berge Henegouwen MI; Lagarde SM; Spaander MCW; Valkema R; Biermann K; Wijnhoven BPL; van der Gaast A; van Lanschot JJB; Doukas M; Nikkessen S; Luyer M; Schoon EJ; Roef MJ; van Lijnschoten I; Oostenbrug LE; Riedl RG; Gisbertz SS; Krishnadath KK; Bennink RJ; Meijer SL;
Ann Surg; 2021 Dec; 274(6):1009-1016. PubMed ID: 31592898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
